P
Pulmonx Corporation (LUNG)
NMS – Real Time Price. Currency in USD
1.17
-0.07 (-5.65%)
At close: Mar 27, 2026, 4:00 PM EDT
1.15
-0.02 (-1.71%)
After-hours: Mar 27, 2026, 5:21 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
1.17
-0.07 (-5.65%)
At close: Mar 27, 2026, 4:00 PM EDT
1.15
-0.02 (-1.71%)
After-hours: Mar 27, 2026, 5:21 PM EDT
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
| Name | Position |
|---|---|
| Dr. Derrick Sung Ph.D. | CFO & COO |
| Dr. Narinder S. Shargill Ph.D. | Senior Vice President of Global Medical & Clinical Affairs |
| Mr. David A. Lehman J.D. | General Counsel & Secretary |
| Mr. Geoffrey Beran Rose | Chief Commercial Officer |
| Mr. Glendon E. French | CEO, President & Director |
| Mr. John B. McKune | VP of Finance & Corporate Controller |
| Mr. Jérôme Erath | Senior VP & GM of International |
| Date | Type | Document |
|---|---|---|
| 2026-03-10 | 10-K | lung-20251231.htm |
| 2026-03-05 | 8-K | d126478d8k.htm |
| 2026-03-04 | 8-K | lung-20260304.htm |
| 2025-11-24 | S-3/A | d935826ds3a.htm |
| 2025-11-12 | 10-Q | lung-20250930.htm |
| 2025-10-27 | 8-K | lung-20251021.htm |
| 2025-09-26 | S-3 | d935826ds3.htm |
| 2025-08-01 | 10-Q | lung-20250630.htm |
| 2025-07-30 | 8-K | lung-20250730.htm |
| 2025-05-30 | SD | formsd-pulmonx2025.htm |
| Mr. Sri Radhakrishnan |
| Chief Science & Technology Officer |
| Ms. Lisa Paul | Chief People Officer |
| Ms. Marcee M. Maroney | Vice President of Marketing |